Precision Neuroscience Partners with UChicago Medicine to Advance Brain-Computer Interface Research for Motor Function Restoration
核心洞察
Precision Neuroscience Corporation (搜索) has launched a clinical partnership with University of Chicago Medicine (搜索) researchers to advance AI-driven sensorimotor function and neuroprosthetics research using brain-computer interface technology.
The collaboration utilizes Precision's Layer 7 (搜索)™ microelectrode array, which has FDA 510(k) clearance and can capture high-resolution neural data for up to 30 days without damaging brain tissue.
The research aims to develop assistive technologies and neurorehabilitation solutions for patients with ALS (搜索) and brainstem stroke (搜索), conditions that cause significant movement and speech deficits.
Precision Neuroscience Corporation (搜索) has formed a clinical partnership with researchers at the University of Chicago Medicine (搜索) to advance brain-computer interface (BCI) technology for motor function restoration. The collaboration focuses on two interconnected areas of neuroscience research: AI-driven sensorimotor function and neuroprosthetics, targeting patients with conditions that cause severe movement and communication deficits.
Advanced Neural Data Capture Technology
The partnership centers on Precision's Layer 7 (搜索)™, a high-density microelectrode array that captures neural activity with groundbreaking spatial resolution. The device transforms the brain's surface into a highly precise data stream and has received FDA 510(k) clearance, enabling researchers to continuously capture neural data in high resolution for up to 30 days. By leveraging AI models, Precision translates this brain activity into code that can inform motor function restoration.
"With Precision's BCI technology, our team can now capture rich neural data without damaging the brain, giving us new ways to study how it understands and generates movement," said Dr. Peter Warnke, director of stereotactic and functional neurosurgery and professor of neurological surgery at UChicago Medicine. "This research could help us better understand the planning and execution of physical actions and can ultimately inform assistive technology devices or neurorehabilitation."
Clinical Research Leadership
Dr. Peter Warnke and Dr. Charles Greenspon lead the clinical research team at UChicago Medicine Sensorimotor Bionics Group, bringing specialized expertise in functional neurosurgery and neuroscience to their respective research programs. The University of Chicago Medicine (搜索) has been at the forefront of human BCI investigation for more than a decade, participating in landmark early-stage clinical trials that helped establish the scientific foundation of the field.
Addressing Critical Medical Needs
The research partnership specifically targets patients with ALS (搜索) and brainstem stroke (搜索), conditions that result in profound loss of movement and speech capabilities. "For people with ALS or brainstem stroke, the loss of movement and speech isn't just a deficit—it is isolation," said Jayme Strauss, chief clinical officer at Precision Neuroscience. "We have very few tools today that can meaningfully address the damage caused by these conditions."
Expanding Clinical Network
The partnership adds UChicago Medicine to Precision's growing clinical research network, which is composed of specialized institutions with the capacity to transform the data generated by Precision's system into clinical meaning and tangible patient outcomes. The collaboration aims to advance understanding of neurological conditions while developing actionable clinical insights that could restore lost functions for affected patients.
Company Development
To date, Precision has tested its device in more than 80 patients and has raised $180 million from leading investors. The company is developing what it describes as the only brain-computer interface designed to be minimally invasive, safely removable, and high-bandwidth, with the goal of creating breakthrough treatments and technology for millions of people worldwide.